BR112016002213A2 - Construtos do fator 15 de diferenciação de crescimento (gdf-15) - Google Patents

Construtos do fator 15 de diferenciação de crescimento (gdf-15)

Info

Publication number
BR112016002213A2
BR112016002213A2 BR112016002213A BR112016002213A BR112016002213A2 BR 112016002213 A2 BR112016002213 A2 BR 112016002213A2 BR 112016002213 A BR112016002213 A BR 112016002213A BR 112016002213 A BR112016002213 A BR 112016002213A BR 112016002213 A2 BR112016002213 A2 BR 112016002213A2
Authority
BR
Brazil
Prior art keywords
constructs
gdf
differentiation factor
growth differentiation
gdf15
Prior art date
Application number
BR112016002213A
Other languages
English (en)
Inventor
Wang Zhulun
Kannan Gunasekaran
Eva Hamburger Agnes
Xiong Yumei
Zhang Yi
Z Sheng Jackie
Veniant-Ellison Murielle
Shimamoto Grant
Min Xiaoshan
Tang Jie
Mock Marissa
Walker Kenneth
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358091&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016002213(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR112016002213A2 publication Critical patent/BR112016002213A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PROTEÍNA DE FUSÃO, DÍMERO E TETRÂMERO, BEM COMO SEUS USOS. São fornecidos construtos compreendendo o GDF15 e seus mutantes. Em várias modalidades, os construtos compreendendo GDF15, e seus mutantes, podem ser de utilidade no tratamento ou melhora de um distúrbio metabólico. Em várias modalidades, a doença ou distúrbio metabólico é a diabetes tipo 2, obesidade, dislipidemia, níveis elevados de glicose, níveis elevados de insulina e nefropatia diabética.
BR112016002213A 2013-07-31 2014-07-31 Construtos do fator 15 de diferenciação de crescimento (gdf-15) BR112016002213A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361860723P 2013-07-31 2013-07-31
PCT/US2014/049254 WO2015017710A1 (en) 2013-07-31 2014-07-31 Growth differentiation factor 15 (gdf-15) constructs

Publications (1)

Publication Number Publication Date
BR112016002213A2 true BR112016002213A2 (pt) 2017-08-29

Family

ID=51358091

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002213A BR112016002213A2 (pt) 2013-07-31 2014-07-31 Construtos do fator 15 de diferenciação de crescimento (gdf-15)

Country Status (35)

Country Link
US (3) US9862752B2 (pt)
EP (2) EP3027642B1 (pt)
JP (4) JP6509852B2 (pt)
KR (3) KR102376451B1 (pt)
CN (2) CN105980400B (pt)
AP (1) AP2016009011A0 (pt)
AR (1) AR097181A1 (pt)
AU (1) AU2014296107B2 (pt)
BR (1) BR112016002213A2 (pt)
CA (1) CA2918624C (pt)
CL (1) CL2016000249A1 (pt)
CR (1) CR20160097A (pt)
CY (1) CY1123836T1 (pt)
DK (1) DK3027642T3 (pt)
EA (2) EA202092386A1 (pt)
ES (1) ES2828670T3 (pt)
HK (1) HK1225738A1 (pt)
HU (1) HUE050630T2 (pt)
IL (1) IL243749B (pt)
JO (1) JO3566B1 (pt)
LT (1) LT3027642T (pt)
MA (1) MA38873B1 (pt)
MX (2) MX369152B (pt)
NZ (2) NZ754961A (pt)
PE (1) PE20160189A1 (pt)
PH (1) PH12016500208B1 (pt)
PL (1) PL3027642T3 (pt)
PT (1) PT3027642T (pt)
SG (1) SG11201600713RA (pt)
SI (1) SI3027642T1 (pt)
TN (1) TN2016000035A1 (pt)
TW (1) TWI648401B (pt)
UA (1) UA116665C2 (pt)
UY (1) UY35686A (pt)
WO (1) WO2015017710A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
BR112014018575A2 (pt) * 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
BR112015018104A2 (pt) 2013-01-30 2017-11-21 Ngm Biopharmaceuticals Inc polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
EP3027642B1 (en) * 2013-07-31 2020-08-19 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
JP2015182969A (ja) * 2014-03-21 2015-10-22 四国化成工業株式会社 トリアゾールシラン化合物、該化合物の合成方法及びその利用
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
RU2017101436A (ru) 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
WO2016018931A1 (en) 2014-07-30 2016-02-04 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
PE20171058A1 (es) 2014-10-31 2017-07-21 Ngm Biopharmaceuticals Inc Composiciones y metodos de uso para tratar trastornos metabolicos
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
AU2017241161B2 (en) 2016-03-31 2022-05-26 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
MX2018014023A (es) 2016-05-24 2019-04-04 Novo Nordisk As Compuestos de citocina inhibidora de macrofagos 1 (mic-1) y uso de estos.
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
KR102010652B1 (ko) * 2017-08-21 2019-08-13 서울대학교병원 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
US11260108B2 (en) 2017-09-10 2022-03-01 Novo Nordisk A/S MIC-1 and GLP-1 for use in the treatment of obesity
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
AU2019253462A1 (en) 2018-04-09 2020-11-26 Amgen Inc. Growth differentiation factor 15 fusion proteins
SG11202012993SA (en) * 2018-07-13 2021-02-25 Genmab As Variants of cd38 antibody and uses thereof
AU2019368816A1 (en) 2018-10-22 2021-05-13 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof
WO2020218827A1 (ko) * 2019-04-23 2020-10-29 주식회사 엘지화학 면역글로불린의 Fc 영역 및 GDF15를 포함하는 융합 폴리펩타이드
TW202110877A (zh) 2019-05-30 2021-03-16 美商安進公司 工程改造鉸鏈區以驅動抗體二聚化
CA3142440A1 (en) 2019-06-07 2020-12-10 Amgen Inc. Bispecific binding constructs
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
US20230002460A1 (en) * 2019-11-26 2023-01-05 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
WO2021118256A1 (ko) * 2019-12-11 2021-06-17 주식회사 엘지화학 O-글리코실화 가능한 폴리펩타이드 영역 및 gdf15를 포함하는 융합 폴리펩타이드
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
WO2022089435A1 (en) 2020-10-27 2022-05-05 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of gdf15 and use thereof
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
AU2022333099A1 (en) * 2021-08-24 2024-02-08 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and uses thereof
TW202342014A (zh) 2022-02-10 2023-11-01 瑞士商諾華公司 １，３－苯并二氧戊環衍生物
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN115028726B (zh) * 2022-03-31 2024-01-09 浙江特瑞思药业股份有限公司 一种抗pd-1纳米抗体及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
WO1999006445A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
KR20020007287A (ko) * 1999-01-07 2002-01-26 추후보정 Ｆｃ 융합 단백질로서 항-비만 단백질의 발현 및 이출
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
CA2716959A1 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
CA2437958C (en) 2001-03-09 2018-10-30 University Of Chicago Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors
JP4422949B2 (ja) 2001-06-26 2010-03-03 武田薬品工業株式会社 ＴＧＦ−βスーパーファミリー産生・分泌促進剤
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7101852B2 (en) 2003-05-30 2006-09-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment and prevention of restenosis
RU2322261C2 (ru) * 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
AU2004282984B2 (en) * 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP2774620A1 (en) 2004-04-13 2014-09-10 St Vincent's Hospital Sydney Limited Method for modulating weight loss
WO2005113585A2 (en) * 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1778275A2 (en) * 2004-08-12 2007-05-02 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
CA2628928A1 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
CN1974601A (zh) * 2005-11-28 2007-06-06 上海新生源医药研究有限公司 一种新型Fc融合蛋白及其生产方法
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2783698A1 (en) 2007-08-16 2014-10-01 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
EP2279419A1 (en) 2008-05-20 2011-02-02 Roche Diagnostics GmbH Gdf-15 as biomarker in type 1 diabetes
CA2732449A1 (en) 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
JP5444363B2 (ja) 2008-10-31 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 慢性腎疾患における予後判定の方法
WO2011063348A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Monomeric antibody fc
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
CA2782814A1 (en) 2009-12-02 2011-06-09 Amgen Inc. Binding proteins that bind to human fgfr1c, human .beta.-klotho and both human fgfr1c and human .beta.-klotho
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
CA2807213C (en) 2010-08-26 2022-06-28 F. Hoffman-La Roche Ag Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
JP6167040B2 (ja) * 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
HUE033008T2 (hu) * 2011-04-13 2017-11-28 Bristol Myers Squibb Co FC fúziós proteinek, amelyek tartalmaznak új linkereket
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
SI2794905T1 (sl) * 2011-12-20 2020-08-31 Medimmune, Llc Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
BR112014018575A2 (pt) * 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
PT2838917T (pt) * 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
US9175076B2 (en) 2012-12-21 2015-11-03 Aveo Pharmaceuticals, Inc. Anti-GDF15 antibodies
BR112015018104A2 (pt) 2013-01-30 2017-11-21 Ngm Biopharmaceuticals Inc polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
EP3027642B1 (en) * 2013-07-31 2020-08-19 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
SG11201609706VA (en) 2014-06-23 2017-01-27 Novartis Ag Site specific protein modifications
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
RU2017101436A (ru) 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
MX2018014023A (es) 2016-05-24 2019-04-04 Novo Nordisk As Compuestos de citocina inhibidora de macrofagos 1 (mic-1) y uso de estos.
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法

Also Published As

Publication number Publication date
IL243749A0 (en) 2016-04-21
NZ754961A (en) 2022-04-29
KR20160038896A (ko) 2016-04-07
AP2016009011A0 (en) 2016-01-31
WO2015017710A1 (en) 2015-02-05
MA38873B1 (fr) 2018-11-30
CN113527512A (zh) 2021-10-22
TWI648401B (zh) 2019-01-21
HK1225738A1 (zh) 2017-09-15
JP6509852B2 (ja) 2019-05-08
SG11201600713RA (en) 2016-02-26
CA2918624A1 (en) 2015-02-05
AU2014296107A1 (en) 2016-02-04
CL2016000249A1 (es) 2016-07-22
EA037355B1 (ru) 2021-03-17
PH12016500208A1 (en) 2016-04-25
JP2023116723A (ja) 2023-08-22
JP6877478B2 (ja) 2021-05-26
EP3763734A1 (en) 2021-01-13
ES2828670T3 (es) 2021-05-27
JP2021113219A (ja) 2021-08-05
CN105980400A (zh) 2016-09-28
PE20160189A1 (es) 2016-05-06
KR20240000642A (ko) 2024-01-02
US20180079790A1 (en) 2018-03-22
JP2016532690A (ja) 2016-10-20
AR097181A1 (es) 2016-02-24
EA201690297A1 (ru) 2016-06-30
US10894814B2 (en) 2021-01-19
PT3027642T (pt) 2020-10-30
MX369152B (es) 2019-10-30
KR102376451B1 (ko) 2022-03-23
EP3027642B1 (en) 2020-08-19
MX2019012848A (es) 2019-11-28
CA2918624C (en) 2024-02-13
NZ717030A (en) 2022-04-29
JO3566B1 (ar) 2020-07-05
KR102616674B1 (ko) 2023-12-29
US9862752B2 (en) 2018-01-09
DK3027642T3 (da) 2020-11-02
EP3027642A1 (en) 2016-06-08
CY1123836T1 (el) 2022-03-24
AU2014296107B2 (en) 2018-07-26
UA116665C2 (uk) 2018-04-25
SI3027642T1 (sl) 2020-11-30
UY35686A (es) 2015-01-30
MX2016001164A (es) 2016-07-26
KR20220038829A (ko) 2022-03-29
LT3027642T (lt) 2020-10-12
PL3027642T3 (pl) 2021-01-11
CR20160097A (es) 2016-07-29
MA38873A1 (fr) 2017-09-29
HUE050630T2 (hu) 2020-12-28
TW201602345A (zh) 2016-01-16
US20210079051A1 (en) 2021-03-18
CN105980400B (zh) 2021-05-07
IL243749B (en) 2018-06-28
TN2016000035A1 (en) 2017-07-05
JP2019178132A (ja) 2019-10-17
EA202092386A1 (ru) 2021-04-30
PH12016500208B1 (en) 2016-04-25
US20160168213A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
BR112016002213A2 (pt) Construtos do fator 15 de diferenciação de crescimento (gdf-15)
BR112014018575A2 (pt) polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
BR112015018104A2 (pt) polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
MX343729B (es) Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos.
BR112013032265A2 (pt) métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
BR112018011002A2 (pt) variantes de fgf21
EA201790377A1 (ru) Антитела к глюкагону и их применения
BR112015014752A2 (pt) compostos e métodos para modulação de cinase, e indicações para isto
JP2016532690A5 (pt)
BR112015014510A2 (pt) agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
DOP2015000185A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos
EA201370126A1 (ru) Человеческие антитела к рецептору глюкагона
WO2013033452A3 (en) Fgf21 for use in treating type 1 diabetes
BR112015027528A2 (pt) polipeptídeo, combinação farmacêutica, métodos de tratamento de um distúrbio metabólico e de obesidade, uso de um polipeptídeo ou de uma combinação farmacêutica, molécula de ácido nucleico, vetor de expressão, e, célula hospedeira
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
AR095555A1 (es) Uso terapéutico de los anticuerpos dirigidos al factor de crecimiento de hepatocitos (hgf)
NI201500057A (es) Métodos para reducir riesgos asociados con insuficiencia cardiaca y factores asociados
BR112015013046A2 (pt) composição comestível, método de redução da amplitude do pico de glicose pós-prandial no sangue ou resposta glicêmica em uma pessoa diabética ou não diabética, método para tratar uma pessoa em necessidade deste para diabetes tipo 2 e uso de uma composição
GT201500168A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
BR112015001885A2 (pt) super agonistas de ação longa de hormônio glicoproteína
WO2013109190A3 (en) Cho-gmt recombinant protein expression
BR112017010981A2 (pt) extrato peptídico e osídico de fruto de schisandra e melhoria na resposta do sistema neurossensorial cutâneo
MX2015015519A (es) Regulador de papalisina.
TH168762A (th) สิ่งที่สร้างขึ้นเป็นโกรทดิฟเฟอเรนชิเอชันแฟคเตอร์ 15 (gdf-15)
Miyamoto CLINICAL APPLICATION OF ELECTRICAL MUSCLE STIMULATION FOR TYPE 2 DIABETES WITH EXERCISE INTOLERANCE

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]